Skip to main content
. 2020 Aug 14;29(11):1385–1396. doi: 10.1177/0961203320947814

Figure 2.

Figure 2.

Patient disposition and withdrawals.

*Patients did not receive belimumab long enough to be included in the next follow-up period/physicians withdrew from the next follow-up period (n = 2, 7–12 months; n = 23, 13–18 months; n = 10, 19–24 months)